Although a putative role has been attributed to inflammation in the pathogenesis of depressive disorders, the relationship of prostaglandins, known mediators of inflammation, and depression has not been elucidated. Clomipramine is an antidepressive drug with a pro-depressive paradoxical effect in adult rats when administrated neonatally. Using this effect as a model of depression, we investigated the differential expression of the cyclooxygenase (COX-2) gene in rat brains. Rats injected neonatally with clomipramine showed depressive-like symptoms in adulthood, as well as decreased levels of the brain-derived neurotrophic factor (BDNF) and a quantitative differential expression of the COX-2 gene (Real Time PCR) and protein (immunohistochemistry) in the hippocampus. As evidenced, the relationship between a key enzyme in the prostaglandin synthesis and biological and behavioral depression-like changes opens an interesting line of investigation regarding the molecular bases of depression and its potential treatment through immunomodulatory drugs.
Introduction
Clinical depression, known as major depression, is one of the most prevalent mental disorders nowadays. It is one of the most disabling illnesses in the world, 1 affecting approximately 17% of United States population. 2 Since many families have a predisposition to depression, a biological vulnerability to depression could be inherited. External events such as a serious loss, chronic illnesses, difficult relationships, financial problems, or any other stressor, often seem to initiate an episode of depression. Very often, a combination of genetic, psychological, and environmental factors are involved in the onset of a depressive disorder. 3 The most acceptable theory to explain depression has been the 'monoamine theory', which proposes a loss or deficits in one or more monoaminergic neurotransmitters. 4 On the other hand, there is great evidence that inflammation has much to do with depression, and that many pro-inflammatory molecules and cytokines 5 could participate in pro-depression mechanisms. Moreover, many antidepressants could attenuate the brain expression or actions of pro-inflammatory cytokines. 6, 7 Cytokines are believed to bind to glial cells, which produce cytokines and other mediators such as prostaglandins, particularly prostaglandin E 2 (PGE 2 ). 8 Regarding prostaglandins, cyclooxygenase-2 (COX-2), a rate limiting enzyme for prostanoids synthesis, is induced during inflammation and participates in inflammation-mediated cytotoxicity 9 and neuronal death. 10 COX-2, also modulates inflammation, glutamate-mediated cytotoxicity, 11 and synaptic plasticity. 12, 13 However, in spite of the close relationship between inflammation and prostaglandins and on the other hand inflammation and depression, the role of COX-2 and prostaglandins was clearly described not in the clinic, neither in animal models of depression.
In order to elucidate the putative changes in the expression of the enzyme COX-2, we chose a pharmacological model of depression consisting of the neonatal administration of clomipramine in rats. 14 In previous studies, this model resembled the behavioral and physiological abnormalities found in human depression. 15 
Results

Behavioral tests
All test performed showed either a statistical difference or a statistical tendency between treated and control animals. Brain-derived neurotrophic factor quantification Densitometry band analysis showed a significant (Po0.05, 't'-test), decrease in the brain-derived neurotrophic factor (BDNF) bands of treated animals compared to control animals (treated 0.85470.071; control 0.97970.071) ( Figure   Figure 1 Assessment of rat weight at the beginning of the treatment (PN8), and after the treatment (PN85). Adult treated animals showed less body weight than controls. At the beginning of the treatment there were no differences in the body weight. White bar, control animals; gray bar, treated animals. *Po0.01 (unpaired 't'-test).
2). This result indicates that BDNF levels were reduced in treated animals, which is thought to be involved in depressive disorders as previously described.
Cyclooxygenase expression
Quantitative COX-2 gene expression on different brain regions was determined by Real Time RT-PCR. The hippocampus of treated animals showed significant differences compared with controls ( Figure 3 ). Cyclooxygenase levels were normalized using GPS1 and actin genes. Samples from the neocortex showed a tendency without significant levels of expression differences.
To confirm that the increase in COX-2 gene expression was in concordance with that of protein localization, brains were cut into 4-mm-thick slices and processed for immuhistochemistry. In concordance with molecular biology results, significant differences in the hippocampus of treated animals were found (Z ¼ 5.29, Po0.05). Additionally, treated animal cerebral cortices at the level of the entorhinal cortex showed a significant number of COX-2 positive cells, compared to control animals (Z ¼ 9.67, Po0.05) ( Figure 4 ).
Discussion
The pharmacological animal model of depression used here, previously described in the literature, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] was validated by behavioral tests and by assessing BDNF, a molecule related to depression. 24, 25 We studied the expression of the COX-2 gene and the localization of its protein, finding an increase in COX-2 levels, which was consistent with previous reports of activation of the immune system in depression disorders. The easy modulation of COX-2 expression by COX-2 inhibitors makes it an interesting point of study to diminish brain inflammation processes occurring in depressive people. We have preliminary results that shown that anti-COX-2 treatment could reverse the behavioral changes observed in clomipramine treated animals (data not shown).
There is evidence of a decreased serotonin level in adult animals treated with clomipramine during the neonatal period. 16, 26 In addition, there is evidence of behavioral and monoaminergic mechanism alterations in adult animals neonatally treated with clomipramine. 19 On the other hand there are results that demonstrated that the depression-like state induced by neonatal exposure to clomipramine are reverted during the adulthood by antidepressants drug which enhance the levels of serotonin. 27 In the present work, treated animals showed statistical differences in the performance of behavioral tests. The Morris water maze is a useful tool to assess the spatial memory ability of rodents. 28 Memory impairment and depression were closely associated in several animal models and cognitive processes, such as learning and memory, which are affected in depression. 29 Thus, we used this classical test to validate our model. Our results indicate that neonatal chronic exposure to clomipramine induces the learning deficits and retarded locomotor effects associated with depression. Recently, the impact of depression on learning and memory has been directly studied in a novel animal model of depressive behavior. The elevated plus maze is widely used to evaluate anxietylike behavior in animals. The test is based on unconditioned responses of animals to a potentially dangerous environment. A combination of maze height, luminosity, and open space is assumed to induce fear or anxiety like behavior, the degree of which is assessed by measuring the amount of time the subject spends in various areas of the maze. Changes in the percentage of time spent on the open arms indicate changes in behaviors associated with anxiety. Our results also validate the model. On the other hand, we have observed that the neonatal treatment with clomipramine makes little differences in the first step of a modified version of Porsolt's forced swim test. However, the animals showed a low tolerance to stress in the climbing step of the test. This behavioral despair could be associated with a depressive-like state and was recently associated in the same model in mice with deficit in the noradrenergic system and the modulation of depression. 31 Anhedonia is an important feature associated with the depressive state. In the present work, we have observed at least three related behaviors associated with an anhedonialike state. Treated animals consumed significantly lower volumes of sucrose, showed less interest for food consumption and also showed less interest for mating. These results are an indirect assessment of loss of interest or of pleasure for daily activities in the treated animals. Although it is hard to extrapolate these results to clinical depression, we must recognize that anhedonia 32 as evaluated in this kind of models, could be associated with a depressive like behavior. The same could be said for the loss of interest in feeding.
In addition to the above behavioral results, we found biological alterations related with that of depression. Western blot for the BDNF showed different levels of expression in the treated animals. Brain-derived neurotrophic factor is a member of the structurally and functionally homologous neurotrophin family. It is the most widely distributed trophic factor in the brain and participates in neuronal growth, maintenance, and use-dependent plasticity mechanisms, such as long-term potentiation and learning. There are several lines of evidence supporting a role for BDNF in the treatment of depression. Recently, it was suggested that the BDNF gene could be a susceptibility gene related in humans with the major depressive disorder 25 If, as presumed in previous works, depression could be related to inflammatory mechanisms, 5, 6, 7, 33 it could be of great interest to study early unspecific inflammation mediators, such as prostaglandins through its inducible enzyme, COX-2, which is induced early during acute inflammation. Functional and structural brain alterations and unspecific immune responses (among them, COX-2 expression) have already been studied in relation with neurological entities. 34 In this work, we observed an upregulation of the COX-2 gene in the brain of treated animals, which coexisted with significant behavioral changes in the adult life of the rats. Another point of interest is the anatomical region in which the changes were demonstrated. Our molecular and histological results showed a significantly elevated expression of the COX-2 gene and also the protein itself. In addition, despite the fact that we could not demonstrate a significant neocortex expression of the COX-2 gene in the treated animals at the Clomipramine-induced depression and COX-2 expression P Cassano et al molecular level, it was evident that the protein was significantly more expressed by immunohistochemistry than in the control group. The hippocampal expression differences could be related to structural and biochemical alterations present in the hippocampus of depressed patients and in models of depression. Imaging studies have reported volumetric alterations of the hippocampus. Additionally, functional alterations have been shown by positron emission tomography with 18Faltanserin (A 2 receptor ligand analog). 35 Moreover, those alterations have been related to memory and learning alterations present in major depression patients, and which correlates to the results obtained from the behavior tests carried out on the depression model animals. Finally, our results regarding the elevated presence of the COX-2 protein in the entorhinal cortex may indicate the existence of a hippocampal-related mechanism. This region of the brain is related to learning and memory and it is connected with the hippocampus.
Regarding the potential importance of COX-2 with inflammatory mechanisms, stress and depressive disorders, there is some newly interesting evidence. Current bibliography suggests some association between anti COX-2 inhibitors and the treatment of psychiatric disorders. 36 On the other hand, an interesting work recently presented an association between COX-2 inhibition and enhancement in glucocorticoid receptor function in vitro. The relation with depressive disorders rests in the putative alteration in that receptor in this kind of affective disorders. 37 Finally, to clarify our findings associated to depressive illness, we should mention that COX-2 differential expression is almost limited to the hippocampus and entorhinal cortex, which are the major areas involved in depressive disorders. [38] [39] [40] [41] In conclusion, the model here presented resembled many of the features of the depressive disorder as previously described. The model also showed an upregulation of the COX-2 gene during the adult life of the animals. This could prove the participation of pro-inflammatory molecules, such as prostaglandins, in the mechanisms associated with the depressive disorder. The next step could be the modulation of prostaglandin synthesis through the many specific drugs currently available.
Materials and methods
Animals and treatment
Experimental procedures on the animals were performed in compliance with international standards for humane handling, care and treatment.
Offspring from Wistar rats mated at our institutional animal facility were born on day 21 of pregnancy (considered as postnatal day (PN ¼ 0). Rats (n ¼ 48), matched in sex, age and weigh (P ¼ 0.771, 't'-test), were randomly assigned to one of two groups: (A) Treated (n ¼ 24), were injected subcutaneously between postnatal days 2 and 14, twice daily with 15 mg/kg clomipramine (Anafranil R, Laboratorio Novartis, Buenos Aires, Argentina), (B) Control (n ¼ 24), were injected subcutaneously between postnatal days 2 and 14, twice daily with saline. The dose was adjusted according to previous bibliography. 16 Clomipramine treated animals and controls were weighed daily and food and water consumption were controlled. On the other hand, the behavior of the animals was observed in detail by qualified personnel to complement the objective validation of the model. As quantification was difficult, qualitative ethological observations, mainly related with sociability, were carried out on a daily basis. 42 To validate the model of depression, we considered three criteria:
1. Objective behavioral tests. 2. A biological change associated with depression. 3. Subjective analysis of daily behavior by qualified personnel, as well as daily record of alimentary and sexual behavior.
Behavioral tests:
To validate the model of depression, clomipramine treated and control rats at the age of 90 days (PN ¼ 90) were subject to a set of behavioral tests previously used to evaluate depression and anxiety like symptoms and learning and memory abilities. Tests were performed in a randomized sequence. Animals were exposed to the elevated plus-maze test of anxiety; 43, 44 the Morris water maze to assess spatial learning and memory; 45, 46 the sucrose consumption test to evaluate depression-induced anhedonia, 32, 47 and the Porsolt forced swim test to evaluate anxiety and depression. 48 
Changes in BDNF:
BDNF is a member of the structurally and functionally homologous neurotrophin family. There are several lines of evidence supporting a role for BDNF in the mechanism and treatment of depression. 24 In this work, BDNF protein levels were quantified by Western Blot technique. 3. Subjective analysis of daily behavior: The behavior of the treated and control animals were observed daily during treatment and until they were killed. A careful record of the alimentary behavior (food and water consumption), social behavior (isolation, aggressiveness, passiveness), and sexual behavior (sexual mating) was conducted.
After behavioral tests, treated and control animals were divided in two groups for molecular analysis and immunohistochemistry. Brains were extracted after decapitation under anesthesia. Hippocampus and entorhinal cortex were obtained by trained people according to bibliography, 49 and RNA extracted. In another equivalent group, animals were anesthetized, and perfused through the heart with 4% paraformaldehide to observe the potential anatomical localization of COX-2 by immunohistochemistry.
Molecular biology techniques
Real time PCR. Reverse transcription was performed on 10 mg of total RNA (previously treated with DNasa to eliminate any DNA contaminate) using 1 mg oligo(dT) 15 (Promega, Madison, WI, USA) and 400 U of Superscript II RNaseH À Reverse Transcriptase (Invitrogen, Buenos Aires, Argentina) following the manufacturer's instructions. Then RNA was degraded using 1 ml RNaseH (Promega). Amplification was performed using QuantiTect SYBR Green PCR and QuantiTect SYBR Green RT-PCR kits (in this case 250 ng of total RNA were used as starting sample) (Qiagen, Valencia, CA, USA) in an iCycler IQ Real-Time Detection System (Bio-Rad, Hercules, CA, USA). The protocol used was the following: 5 min at 941C, 40 cycles of 45 s at 941C, 30 s at the respective melting temperature (53 or 591C) and 15 s at 721C. In all cases, similar results were obtained when PCR were performed using RNA or cDNA as sample.
Beta-actin and G protein pathway suppressor 1 (GPS1) were used as housekeeping genes. The primers were designed using Primer Premier 5 (Biosoft International, Palo Alto, CA, USA).
The COX-2 primers were designed according to gene bank S67722 sequence and were: Forward, Analysis of relative gene expression was performed using the 2 ÀDDCt method. 50 We compared COX-2 expression to GPS1 and actin average.
Western blot technique
Hippocampus samples were homogenized in RIPA buffer (50 mM Tris-HCl pH ¼ 7.4, 150 mM NaCl, 0,5% deoxycholic acid, 1% Nonidet P-40, 0,1% SDS), containing proteinase inhibitors (10 ml/ml Protease inhibitor cocktail, Sigma P8340). After homogenization, the samples were centrifuged at 10 000 g at 41C for 10 min to remove unbroken cells and nuclei. To detect BDNF, proteins in the supernatant were separated by sodium dodecyl sulfate-poliacrylamide gel electrophoresis (SDS-PAGE) on 8% acrylamide gels as previously described. 51 Proteins were transferred to nitrocellulose membranes, blocked in 5% dried milk in TBS buffer for 1 h, incubated with anti-BDNF antibody (Santa Cruz Biotechnology, sc-20981, 1: 200) and antiactin antibody (Sigma A5316, 1:1000) for 1 h at room temperature. Membranes were washed five times in TBS and incubated with HRP-conjugated anti-rabbit IgG (Dako code no P 0160, 1/2000) and HRP-conjugated anti-mousse IgG (Dako code no P0447, 1:1000) for 1 h at room temperature. Immunoreactive bands were visualized using the enhanced chemiluminescence method (SuperSignal West Pico Chemiluminescent Substrate, Prod. no 34080). Hepatocyte homogenate was used as actin positive control and BDNF negative control. Bands were analyzed using ImageScion Software.
Immunohistochemistry
Brains were removed, fixed for 24 h in 4% paraformaldehide, embedded in paraffin and cut in coronal sections of 4 mm thick. After removing the paraffin, sections were washed in phosphate-buffer saline (PBS) at pH 7.2. Antigen retrieval was performed with citrate buffer (pH 6.7) in high-power microwave oven with the following protocol: 15 min at 921C, 15 min at room temperature, 15 min at 921C and 1 h at room temperature.
Incubation was carried out with goat serum (Protein Block, BioGenex, San Ramon, USA) for 2 h followed by an overnight incubation with polyclonal COX-2 antibody (Cayman Chemical, Ann Arbor, MI, USA, dilution 1/200). Samples were washed for 15 min in PBS and incubated with the secondary antibody Multilink ((Laboratorio Biogenex dilution 1/20) for 2 h. After a 15-min wash in PBS, a final incubation was done in a Fluorescein-Streptavidin complex (Vector Lab., Burlangame, USA, dilution 1/50) for 2 h and visualized with a fluorescence microscope and photographed using a Nikon Optiphot microscope.
Coronal sections were evaluated according to a rat brain atlas based on fixed stereotaxic coordinates (The Rat Brain in Stereotaxic Coordinates -The New Coronal Set by George Paxinos, Charles Watson, Academic Press; 5th edition, November 10, 2004) . To quantify the results, analysis was done using an image analyzer (CAS system s , Raritan, NJ, USA). Quantification was made by triplicate, counting three random fields and the statistical difference was calculated using the 'Z' proportion test, a ¼ 0.05.
Biostatistical analysis
To assess quantitative differences among treated animals or controls regarding different variables, a software package was utilized. 52 All molecular biology and immunohistochemistry results were controlled with adequate positive and negative controls.
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